157 related articles for article (PubMed ID: 37606763)
21. Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction.
Xiao JW; Liu ZL; Ye PC; Luo YJ; Fu ZM; Zou Q; Wei SJ
World J Gastroenterol; 2015 Sep; 21(34):9999-10007. PubMed ID: 26379405
[TBL] [Abstract][Full Text] [Related]
22. Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma.
Lee IS; Ahn JY; Yook JH; Kim BS
World J Surg Oncol; 2017 Jan; 15(1):28. PubMed ID: 28100248
[TBL] [Abstract][Full Text] [Related]
23. Lymph Node Ratio Is an Independent Prognostic Factor for Patients with Siewert Type II Adenocarcinoma of Esophagogastric Junction: Results from a 10-Year Follow-up Study.
Zhang Y; Liu D; Zeng D; Chen C
J Gastrointest Cancer; 2021 Sep; 52(3):983-992. PubMed ID: 32954465
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Prognostic Abilities Among Preoperative Laboratory Data Indices in Patients with Resectable Gastric and Esophagogastric Junction Adenocarcinoma.
Urabe M; Yamashita H; Watanabe T; Seto Y
World J Surg; 2018 Jan; 42(1):185-194. PubMed ID: 28741195
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan.
Hosokawa Y; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kato Y; Daiko H; Nishimura M; Katsumata K; Sugiyama Y; Kinoshita T
Ann Surg Oncol; 2012 Feb; 19(2):677-83. PubMed ID: 21822549
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological Significance of STAT3 and p-STAT3 among 91 Patients with Adenocarcinoma of the Esophagogastric Junction.
Ma RJ; Zheng QM; Zhang N; Sun ZG
Dis Markers; 2022; 2022():9311684. PubMed ID: 36225196
[TBL] [Abstract][Full Text] [Related]
27. Unchanging trend of esophagogastric junction adenocarcinoma in Korea: experience at a single institution based on Siewert's classification.
Chung JW; Lee GH; Choi KS; Kim DH; Jung KW; Song HJ; Choi KD; Jung HY; Kim JH; Yook JH; Kim BS; Jang SJ
Dis Esophagus; 2009; 22(8):676-81. PubMed ID: 19222529
[TBL] [Abstract][Full Text] [Related]
28. Survival nomogram for patients with metastatic siewert type II adenocarcinoma of the esophagogastric junction: a population-based study.
Chen K; Deng X; Yang Z; Yu D; Zhang X; Zhang J; Xie D; He Z; Cheng D
Expert Rev Gastroenterol Hepatol; 2020 Aug; 14(8):757-764. PubMed ID: 32552040
[TBL] [Abstract][Full Text] [Related]
29. Immune Infiltration Subtypes Characterization and Identification of Prognosis-Related lncRNAs in Adenocarcinoma of the Esophagogastric Junction.
Hu X; Wu L; Liu B; Chen K
Front Immunol; 2021; 12():651056. PubMed ID: 34122409
[TBL] [Abstract][Full Text] [Related]
30. Clinical and prognostic features of E-cadherin in adenocarcinoma of the esophagogastric junction patients.
Hu K; Zheng QM; Wang YP; Zhao MM; Sun ZG
Eur J Cancer Prev; 2023 Mar; 32(2):119-125. PubMed ID: 36484275
[TBL] [Abstract][Full Text] [Related]
31. Gastroesophageal junction adenocarcinoma.
Swisher SG; Pisters PW; Komaki R; Lahoti S; Ajani JA
Curr Treat Options Oncol; 2000 Dec; 1(5):387-98. PubMed ID: 12057146
[TBL] [Abstract][Full Text] [Related]
32. Adenocarcinomas of the esophagogastric junction: experiences at a single institution in China.
Zhang H; Wang W; Cheng Y; Song Y; Zhu K; Dang C
World J Surg Oncol; 2013 Jul; 11():155. PubMed ID: 23849250
[TBL] [Abstract][Full Text] [Related]
33. Tumor size predicts worse prognosis in esophagogastric junction adenocarcinoma.
Takeda FR; Ramos MFKP; Pereira MA; Sallum RAA; Ribeiro Junior U; Nahas SC; Cecconello I
Updates Surg; 2022 Dec; 74(6):1871-1879. PubMed ID: 35776245
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of TAZ and β-catenin expression in adenocarcinoma of the esophagogastric junction.
Sun L; Chen F; Shi W; Qi L; Zhao Z; Zhang J
Diagn Pathol; 2014 Jul; 9():125. PubMed ID: 25029906
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of the superiority of different TNM staging systems in Siewert III adenocarcinoma of esophagogastric junction].
Lu Y; Xi H; Xie T; Qiu Z; Wang X; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):143-148. PubMed ID: 30799536
[TBL] [Abstract][Full Text] [Related]
36. [Analysis of survival and prognosis of Siewert Ⅱ/Ⅲ esophagogastric junction adenocarcinoma patients with non-operative acute upper gastrointestinal hemorrhage].
Tian L; Yu L
Zhonghua Yi Xue Za Zhi; 2020 Jun; 100(24):1881-1885. PubMed ID: 32575932
[No Abstract] [Full Text] [Related]
37. Preoperative pre-albumin predicts prognosis of patients after gastrectomy for adenocarcinoma of esophagogastric junction.
Han WX; Chen ZM; Wei ZJ; Xu AM
World J Surg Oncol; 2016 Nov; 14(1):279. PubMed ID: 27809860
[TBL] [Abstract][Full Text] [Related]
38. Clinical Outcome in Patients with Carcinoma of the Esophagogastric Junction Treated with Neoadjuvant Radiochemotherapy or Perioperative Chemotherapy: A Two-Center Retrospective Analysis.
Wundsam HV; Doleschal B; Prommer R; Venhoda C; Schmitt C; Petzer A; Metz-Gercek S; Rumpold H
Oncology; 2020; 98(10):706-713. PubMed ID: 32516775
[TBL] [Abstract][Full Text] [Related]
39. [Effect of number of metastatic lymph nodes and metastatic lymph node ratio on the prognosis in patients with adenocarcinoma of the esophagogastric junction after curative resection].
Zhang H; Chen C; Yue J; Ma M; Ma Z; Yu Z
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):141-6. PubMed ID: 24796465
[TBL] [Abstract][Full Text] [Related]
40. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
